Martin Bitzan, MD

Research interests are the pathogenesis and novel treatments of hemolytic uremic syndrome, a group of rare, but diverse and challenging diseases in young children. Current projects include an analysis of the incidence, clinical presentation and outcome of infections by Shiga toxin (verotoxin) producing Escherichia coli and the feasibility of novel, antibody-based therapies for HUS.A second area of clinical investigations is infectious complications in children with renal transplant and with glomerular diseases. One project studies the evolution of Polyomavirus infections in the renal allograft recipient. Another project focuses on a novel treatment strategy for children with frequently relapsing nephrotic syndrome in an attempt to reduce the exposure to glucocorticoids and calcineurin inhibitors.Nephrology, Pediatrics, Kidney transplantation, Hemolytic Uremic Syndrome, nephrotic syndrome, Shiga toxin, verotoxin, Escherichia coli, nephritic syndrome, glomerular diseases, Immunology, Polyomavirus infection, Monoclonal antibody therapy